Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

blonca9
Feb 26, 2024
1 min read

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies and how Lyell is manufacturing its products to improve potency. Plus, a discussion on ROR1 as a solid tumor target for CAR-T.

Recent Posts

See All

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight